CompletedNot Applicable

Statins and Post-ERCP Acute Pancreatitis (Stark Project)

Spain1,016 participantsStarted 2017-01-10

Plain-language summary

Post-endoscopic retrograde cholangiopancrepatography (ERCP) acute pancreatitis (PEAP) is a frequent complication of this endoscopic procedure. Chronic statin intake has been linked to lower incidence and severity of acute pancreatitis (AP). Periprocedural rectal administration of non-steroidal anti-inflammatory drugs is protective against PEP, but the role of chronic acetylsalicylic acid (ASA) treatment is unclear. The aim of the study is to investigate whether statins and chronic ASA intake are associated with lower risk of PEAP.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients ≥ 18 years old scheduled for ERCP and willing to participate were included. Exclusion Criteria: * Patients with ongoing AP * Surgically altered biliary anatomy (such as hepatico-jejunostomy or choledoco-duodenostomy) * Failure to reach the papilla * Patients undergoing ERCP for stent removal or exchange

What they're measuring

To assess the incidence and relative risk of PEAP according to statin use.

Timeframe: 2 years

Trial details

NCT IDNCT06367322

SponsorHospital General Universitario de Alicante

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-07-31

View on ClinicalTrials.gov More Post-ERCP Acute Pancreatitis trials